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The CATERPILLER (CLR, also NOD and NLR) proteins share
structural similarities with the nucleotide binding domain (NBD)-
leucine-rich repeat (LRR) superfamily of plant disease-resistance
(R) proteins and are emerging as important immune regulators in
animals. CLR proteins contain NBD-LRRmotifs and are linked to a
limited number of distinct N-terminal domains including transac-
tivation, CARD (caspase activation and recruitment), and pyrin
domains (PyD). The CLR gene,Monarch-1/Pypaf7, is expressed by
restingprimarymyeloid/monocytic cells, and its expression in these
cells is reduced by Toll-like receptor (TLR) agonists tumor necrosis
factor (TNF)  and Mycobacterium tuberculosis. Monarch-1
reduces NFB activation by TLR-signaling molecules MyD88,
IRAK-1 (type I interleukin-1 receptor-associated protein kinase),
and TRAF6 (TNF receptor (TNFR)-associated factor) as well as
TNFR signaling molecules TRAF2 and RIP1 but not the down-
stream NFB subunit p65. This indicates that Monarch-1 is a neg-
ative regulator of both TLR and TNFR pathways. Reducing Mon-
arch-1 expression with small interference RNA in myeloid/
monocytic cells caused a dramatic increase in NFB activation and
cytokine expression in response to TLR2/TLR4 agonists, TNF, or
M. tuberculosis infection, suggesting that Monarch-1 is a negative
regulator of inflammation. BecauseMonarch-1 is the first CLR pro-
tein that interferes with both TLR2 and TLR4 activation, themech-
anism of this interference is significant. We find that Monarch-1
associates with IRAK-1 but notMyD88, resulting in the blockage of
IRAK-1 hyperphosphorylation. Mutants containing the NBD-LRR
or PyD-NBD also blocked IRAK-1 activation. This is the first exam-
ple of a CLR protein that antagonizes inflammatory responses ini-
tiated by TLR agonists via interference with IRAK-1 activation.
Plants have several classes of disease-resistant genes (R genes) that
enable host defense to a wide variety of pathogens. A major class of R
genes encodes proteins that contain an N-terminal Toll-like receptor
(TLR)2/IL-1 receptor or leucine zipper domain followed by a nucleotide
binding domain (NBD) and a C-terminal leucine-rich repeat (LRR). In
mammals the class II transactivator and NOD1/NOD2 proteins were
initially identified as proteins with a similar arrangement of NBD and
LRR domains. More recently, our laboratory identified a 20 member
family of genes in humans that we called the CATERPILLER (CARD,
transcription enhancer, r(purine) binding, pyrin, lots of leucine repeats)
gene family (1). Subsequently, others described a similar family and
designated it as NOD (2, 3), whereas others described a subgroup with a
pyrin domain designated as the NALP, PAAD/PAN, and PYPAF fami-
lies (3–6). By definition, all CLR proteins contain NBD-LRRmotifs and
are linked to a limited number of distinctN-terminal domains including
transactivation, CARD (caspase activation and recruitment), and pyrin
domains (PyD) (1). A great majority of CLR proteins contain a PyD,
originally defined as a domain within the PYRIN protein that has been
linked to familial Mediterranean fever (MEFV) (7). The PyD has
recently been characterized as a member of the death domain-fold
superfamily (8). This report describes the function of one such PyD
containing NBD-LRR protein, Monarch-1.
A strong clue that CLR proteins are likely to be critical regulators of
the immune response, inflammation, and host response to pathogens is
the genetic linkage of several CLR gene products to susceptibility to
autoinflammatory and immunodeficiency disorders. For example,
mutations in MHC2TA are linked to a severe immunodeficiency Bare
Lymphocyte Syndrome (9); mutations in NOD2/CARD15 are associ-
ated with a subpopulation of patients with Crohn disease and Blau syn-
drome (10–13). Mutations in the CIAS1/Pypaf1/NALP3 gene are asso-
ciated with a variety of clinical autoinflammatory syndromes, including
familial cold autoinflammatory syndrome, chronic infantile neurologi-
cal cutaneous and articular syndrome, or neonatal-onset multisystem
inflammatory disease and Muckle-Wells syndrome (14–18). Their
important role in bacterial infection is underscored by a number of
recent studies showing that the NOD1 protein mediates recognition of
a peptidoglycan derived primarily fromGram-negative bacteria (19, 20),
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whereasNOD2mediates the recognition ofmuramyl dipeptide (19, 21).
These findings support the provocative idea that this family of proteins
constitutes intracellular sensors of bacterial products and that muta-
tions within these genes lead to a dysregulated inflammatory response.
In addition to the role of CLR proteins as intracellular cytoplasmic
mediators, TLRs in mammals have rapidly emerged as predominant
molecules by which the innate immune system senses and responds to
microbial pathogens (22, 23). There are 13 TLRs that recognize an array
of microbial products derived from bacteria, viruses, and fungi (24–26).
TLR signal transduction is initiated by stimulation followed by the for-
mation of an intracellular signaling complex with adapter proteins, the
predominant one being MyD88 (27). An early step in TLR signaling is
the recruitment of the serine/threonine kinase, IRAK-1, to activated
receptor complexes. IRAK-1 activation is regulated by sequential phos-
phorylation events (28). Hyperphosphorylation of IRAK-1 is important
for TLR signal transduction as it results in a decreased affinity for the
TLR receptor complex and enables the association of IRAK-1 with the
TRAF6 complex, leading to activation of NFB and its functional
sequelae (29).
We have recently characterized a CLR gene designated asMonarch-1
(30), also known asPypaf7 (6).Monarch-1 is expressed primarily by cells
of the myeloid lineage, including monocytes and granulocytes. This
study shows thatMonarch-1 interferes with IRAK-1 function, resulting
in the repression of TLR signaling, and thus, represents a novel negative
regulator of inflammatory responses.
EXPERIMENTAL PROCEDURES
Reagents—The TLR2 agonist, the synthetic lipoprotein S-[2,3-bis-
(palmitoyloxy)-(2-RS)-propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-Lys-4-OH
trihydrochloride (Pam3Cys) (ECM) was used at a final concentration of
100 ng/ml. Initially, lipopolysaccharide (LPS) derived from Escherichia
coli 026:B6 (Sigma-Aldrich) was used at a final concentration of 200
ng/ml; however, for most of the experiments protein-free, phenol/wa-
ter-extracted E. coliK235 LPS prepared by themethod ofMcIntire et al.
(31) was used to preclude the contribution of non-TLR4 contaminants
that are often found in commercial LPS preparations (32).
Primary Cell Isolation and Stimulation—Peripheral blood mononu-
clear cells (PBMC)were isolated frombuffy coats (American RedCross)
using lymphocyte separation media (ICN, Costa Mesa, CA). For adher-
ent cell purification, cells were plated at 1 108 cells/150 mM plate and
allowed to adhere for 2 h at 37 °C. Non-adherent cells were removed by
washing three times with phosphate-buffered saline and replaced with
fresh media. Granulocytes were isolated from the red blood cell pellet
after lymphocyte separation media purification after ammonium, chlo-
ride, potassium buffer red blood cell lysis. Granulocytes were plated at
2 107 cells/150mMplate. Cells were stimulated for 1 hwith 200 ng/ml
commercial LPS from E. coli (LPS 026:B6; Sigma-Aldrich) or, where
noted, protein free, phenol/water-extracted E. coli LPS K235 prepared
as described in McIntire et al. (31), 1 g/ml commercial peptidoglycan
(Sigma), or 100 ng/ml Pam3Cys (ECM).
Expression Plasmids—The complete open reading frame of Mon-
arch-1was cloned into pcDNA-3 (Invitrogen) as described (26). Expres-
sion plasmids and reporter vectors included HA-MyD88 (33),
HA-IRAK-1, HA-TRAF6 (34), 3AP-1 luc (35), HA-TRAF2, Myc-
RIP1, p65, NFB luc (36), and ELAM-luciferase.Monarch-1 truncation
mutants were amplified by PCR and cloned into the pcDNA3.1 V5/HIS
vector following the manufacturer’s recommendations (Invitrogen).
Tissue Culture Cells and Conditions—HEK293T cells were main-
tained in Dulbecco’s modified Eagle’s medium (high glucose) supple-
mentedwith 10% fetal calf serum, 5mM L-glutamine, and streptomycin-
penicillin. Undifferentiated THP-1 cells were maintained in RPMI 1640
supplemented with 10% fetal calf serum, 2 mM L-glutamine, 1 mM
sodium pyruvate, 0.1 mM nonessential amino acids, and streptomycin-
penicillin. All cells were grown at 37 °C with 5% CO2.
Luciferase Reporter Gene Assays—For transfections 2  105
HEK293T cells were plated in 12-well plates followed by transfection
using FuGENE 6 transfection reagent (Roche Applied Science) follow-
ing the manufacturer’s recommended protocol. For analysis of TLR
receptor signaling molecule induction of NFB activity, cells were co-
transfected with 250 ng of pNFB-luc, 100, 250, or 500 ng of
pcDNA3-HA vector, or HA-tagged Monarch-1, and 250 ng of HA-
MyD88, FLAG-IRAK-1 HA-TRAF6, p65, HA-TRAF2, Myc-RIP1 or
stimulated with 10 ng/ml TNF to induce NFB reporter activity. For
IL-6 gene reporter luciferase assays, 1 104 HEK293T cells were plated
in 12-well plates and transfected with 10 ng of IL-6-luc and 10, 20, 50,
and 100 ng of pcDNA3-HA vector or HA-tagged Monarch-1. DNA
concentrations were consistent for each transfection. At 24 h post-
transfection, cells were lysed in 1 reporter lysis buffer (Promega), and
luciferase assays were performed per the manufacturer’s instructions.
TLR Reporter Assays—HEK293T cells (2 105 cells/well in a 12-well
plate) were co-transfected for 3 h with pFLAG-huTLR4 (7.5 ng/well),
pCDNA3-huCD14 (300 ng/well), pEFBOS-HA-huMD-2 (3 ng/well), or
Monarch-1 (0–500 ng/well) together with the NFB reporter (500
ng/well) and pCMV1- gal (100 ng/well). The final DNA quantity was
adjusted to 1.5 g/well, each with the pCDNA-HA vector using Super-
Fect transfection reagent (Qiagen Inc.). Cells were recovered for 20 h,
washed, and stimulated with phenol purified LPS at different concen-
trations for 5 h. Cells were lysed and -galactosidase (Tropix, Galacto-
Light system), and luciferase (Promega, luciferase assay system) activi-
ties were analyzed.
Transfection, Immunoprecipitation, and Western Analysis—
HEK293T cells were transfected with the indicated plasmid cDNA
using FuGENE 6. Cells were lysed in buffer containing 1%TritonX-100,
150 mM NaCl, 50 mM Tris, pH 8, 50 mM NaF, 2 mM EDTA, plus a
protease inhibitormixture (RocheApplied Science). Protein concentra-
tions were determined by Bradford assay (Bio-Rad), and equivalent
amounts of cellular extract were used in subsequent immunoprecipita-
tions. Immunoprecipitates were washed four times in lysis buffer and
eluted by boiling in Laemmli sample buffer. Samples were fractionated
by SDS-PAGE and transferred to nitrocellulose.
Immunoblots were probedwith the indicated primary antibodies and
visualized by enhanced chemiluminescence (Pierce): anti-HA 3F10
(Sigma), mouse monoclonal anti-HA 12CA5 and anti-HA3F10-HRP
(Roche Applied Science), anti-IRAK-1 C-20 and anti-actin-HRP (Santa
Cruz), or anti-FLAG M2-HRP (Sigma). Anti-V-5 was obtained from
Invitrogen.
Generation of Antibodies Specific for HumanMonarch-1 and Expres-
sion Analysis—Polyclonal antisera against humanMonarch-1 was gen-
erated by immunization of rabbits with keyhole limpet hemocyanin-
conjugated Monarch-1 peptide (RGQREDLVRDTPPGC). The IgG
from the polyclonal antiserum was purified with protein G-Sepharose
affinity chromatography utilizing the manufacturer’s protocols. A
mouse monoclonal Monarch-1 antibody was generated from mice
immunized with hexahistidine-taggedMonarch-1 (amino acids 1–593)
expressed in E. coli and purified on nickel nitrilotriacetic-agarose (Qia-
gen) using denaturing conditions described in the manufacturer’s pro-
tocol. THP-1 cells stimulated with purified LPS for the indicated time
points were lysed in lysis buffer (50mMTris-HCl, pH 8.0, 150mMNaCl,
1%Nonidet P-40) supplementedwithComplete protease inhibitormix-
ture (Roche Applied Science). Protein concentrations were determined
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by the Bradford assay (Bio-Rad), and equivalent amounts of cellular
extract were used in subsequent immunoprecipitations. Immunopre-
cipitation of Monarch-1 was accomplished utilizing the rabbit anti-
Monarch-1 peptide IgG. To control for immunoprecipitation efficiency
and recovery, a rabbit polyclonal antibody for actin (I19, Santa Cruz)
was included in the immunoprecipitation reaction. Monarch-1 and
actin immune complexes were precipitated with protein A-agarose
beads. Immunoprecipitates were washed 2 times in lysis buffer and
eluted by boiling in 60 l of Laemmli sample buffer. Samples were
fractionated by SDS-PAGE and transferred to nitrocellulose. Immuno-
blots were probed with mouse monoclonal anti-Monarch-1 and HRP-
conjugated anti-actin antibody (C11, Santa Cruz) and visualized by
enhanced chemiluminescence (Pierce).
RNA Preparation and Real-time PCR—Total RNA was isolated
according using Trizol reagent (Invitrogen) following the manufactur-
er’s protocol. Real-time PCRwas performedwith the TaqMan sequence
detection system (Applied Biosystems):Monarch-1 forward 5-AGAG-
GACCTGGTGAGGGATAC-3, reverse 5-CTTCCAGAAGGCAT-
GTTGAC-3, probe 5- CCCGTCCTCACTTGGGAACCA-3, IL-6
forward 5-GGTACATCCTCGACGGCATCT-3, reverse 5-GTGC-
CTCTTTGCTGCTTTCAC-3, probe 5-TGTTACTCTTGTTACA-
TGTCTCCTTTCTCAGGGCT-3; 18 S forward 5-GCTGCTGGCA-
CCAGACTT-3, reverse 5-CGGCTACCACATCCAAGG-3, probe
5-CAAATTACCCACTCCCGACCCG-3. All results are normalized
to 18 S ribosomal RNA internal controls and are expressed in relative
numbers.
Monarch-1-specific Small Interference RNA (siRNA) Construction—
Wild-type and mutant human Monarch-1 short hairpin RNAs were
stably expressed in the human THP-1monocyte cell line by infection of
the HSPG retrovirus containing short hairpin RNA transcription cas-
settes driven by the H1 RNA promoter and a separate cassette contain-
ing green fluorescent protein driven by the phosphoglycerate kinase
promoter. The targeted sequences are GTCCATGCTGGCACA-
CAAG, and the mutant sequence is GTCCATGCTAACACACAAG
(siRNA#1), and GGACATCAACTGTGAGAGG, and the mutant
sequence is GGACATCGGCTGTGAGAGG (siRNA#2).
Promoter-Reporter Retroviral Plasmids—pHermes-Bluc was
derived from pHRSpuro-GUS (a gift of H. Blau, Stanford University), a
retroviral vector bearing a self-inactivating 3 long terminal repeat
(LTR) that lacks promoter and enhancer elements (37). A fragment of
pGL3basic (Promega) bearing the transcription silencer, multicloning
site, firefly luciferase-coding sequence was inserted into pHRSpuro-
GUS. This yielded pHermes-luc. pHermes-Bluc was constructed by
inserting the 5 NFB response element and TATA box from
pNFBluc (Stratagene) into pHermes-luc. Transduction with
pHermes-Bluc retrovirus results in the integration of a synthetic pro-
moter-reporter gene into the host genome that has no retroviral LTR-
driven transcription, because the self-inactivating 3 LTR, which lacks
promoter and enhancer elements, determines the sequences of both the
5 and 3 LTRs of the integrated retroviral genome. Reporter luciferase
retroviral supernatants were generated as described and used for infec-
tion of THP-1 cells. Cells were stimulated for 6 h with LPS followed by
luciferase assay (Promega) as per themanufacturer’s recommendations.
Retroviral Infections—The A293T cell line were co-transfected with
pHSPG-667 (siRNA#1) or pHSPG-1504 (siRNA#2). Monarch-1-spe-
cific siRNAvectors or pHermes-Bluc and co-transfectedwith pVSV-G
(38) and Pgag-pol (38) in 60-mm dishes. Retroviral supernatants (3
ml/well) were collected 48 and 72 h later, clarified by centrifugation, and
used to infect 106 THP-1 cells by spinning for 3 h at 2500 rpm at 22 °C.
Infection was repeated twice on successive days. For Monarch-1-spe-
cific siRNAs, THP-1 cells were purified to greater than 95% green fluo-
rescent protein-positive using fluorescence-activated cell sorting and
used in experiments as pools.
ELISA—THP-1 Monarch-1 siRNA cell populations were stimulated
with purified K235 LPS at 200 ng/ml for 24 h followed by analysis of IL-6
protein expression. The IL-6 cytokine levels in cell supernatants were
analyzed by sandwich ELISA using antibody pairs and protocols recom-
mended by R&D Systems. The sensitivity of the assays was 16 pg/ml
IL-6.
Mycobacterium tuberculosis Infection—THP-1 cells were infected
with M. tuberculosis strain H37Rv. M. tuberculosis was grown to early
log phase in Middlebrook 7H9 with oleic acid, albumin, dextrose, cata-
lase media. Colony-forming units/ml were determined by plating on
Middlebrook 7H10 with oleic acid, albumin, dextrose, catalase media
from actively growing cultures A  2.5  108. Bacilli were washed in
0.5% Tween 80, phosphate-buffered saline. Briefly, 2 106 THP-1 cells
were seeded in 6-well, flat-bottom cell culture plates 1 day before infec-
tion and incubated at 37 °C. Bacteria were added at a multiplicity of
infection of 10 for THP-1 cells. Infection was evaluated by measuring
colony-forming units. THP-1 cells were collected at the time points
indicated; RNA was made using Trizol reagent (Invitrogen) and evalu-
ated forMonarch-1 or IL-6 expression by real-time PCR.
Cytokine Bead Array—THP-1Monarch-1 siRNA#1 cell populations
were stimulated with purified E. coli K235 LPS at 200 ng/ml, with
Pam3Cys at 100 ng/ml or with TNF at 20 ng/ml for 24 h followed by
analysis of cytokine protein expression. The cytokine levels in cell
supernatants were analyzed by Human Inflammation Cytokine Bead
Array using antibody pairs and protocols recommended by R&D
Systems.
RESULTS
Expression of Monarch-1 Is Decreased by TLR Signaling in PBMC—
Monarch-1 is found primarily in cells of the myeloid and monocytic
lineage (6, 30) that represent a first line of defense against invading
microorganisms. These cell types can discriminate among different
pathogens via the capacity of their TLRs to sense pathogen-associated
molecular patterns (39). This causes a very rapid defensive response
including the up-regulation of inflammatory and antimicrobial genes.
Because of the highly restricted expression ofMonarch-1 to cells of the
innate immune system (30), we hypothesized that activation of cells via
TLRs may influence the expression level of Monarch-1. To test this,
human primary adherent PBMC or granulocytes were isolated and
exposed to TLR agonists. After 1 h of treatment with LPS from E. coli,
which activates TLR4, or peptidoglycan, which activates TLR2, Mon-
arch-1 expression was significantly reduced in both cell types (Fig. 1, A
and B). Because of the concern of contaminants in commercial prepa-
rations of TLR agonists, highly purified LPS was prepared by phenol
purification (32). Pam3Cys, the pure synthetic agonist for TLR2, was
used in concert to specifically activate TLR2. Analysis of Monarch-1
expression in granulocytes stimulated with phenol-purified LPS and
synthetic Pam3Cys for 1 h confirmed that Monarch-1 expression is
down-regulated after TLR activation (Fig. 1C).Monarch-1 expression is
down-regulated upon exposure of PBMC toTNF(30). To compare the
level of down-regulation to that observed for LPS, human PBMC were
stimulated for 1 and 6 h with phenol LPS or TNF. A similar reduction
ofMonarch-1mRNAwas observed at 1 h for all treatments (Fig. 1D). At
6 h post-stimulationMonarch-1 expressionwas further down-regulated
by LPS andTNF stimulation. This suggests thatMonarch-1 is reduced
to similar levels after stimulation of human PBMC with LPS or TNF.
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In the humanmonocytic cell line, THP-1,Monarch-1 expression was
also down-regulated by exposure to purified LPS for 1 h, and a further
reduction was observed at 3 h (Fig. 1E). Additionally, Monarch-1 pro-
tein level, measured by immunoblot analysis with antibodies raised
against recombinant Monarch-1, was decreased in THP-1 cells after
exposure to Pam3Cys over a 6-h time period with respect to untreated
cells (Fig. 1F). It was necessary to immunoprecipitate Monarch-1 pro-
tein followed by immunoblotting, as endogenous Monarch-1 has been
difficult to detect in cell lysates. Taken together these data indicate that
Monarch-1 expression is down-regulated after exposure of cells to TLR
agonists. This suggests that down-regulation of Monarch-1 may be
required for the normal defensive response to microorganisms.
Monarch-1Down-regulates TLR- andTNF-inducedNFBActivation—
The decrease in Monarch-1 expression after TLR and TNF stimula-
tion suggested that the down-regulation of Monarch-1 mRNA expres-
sion may be necessary for an antimicrobial response to occur. If this
were the case, Monarch-1 would be predicted to exert inhibitory effects
on steady-state cells and to initially dampen potentially overzealous
pro-inflammatory activities that are activated by TLR agonists or by
microbial infection. To test this hypothesis, we co-transfected the
HEK293T epithelial cell line with expression vectors for TLR4, MD-2,
and CD14 to reconstitute the TLR4 receptor complex. The ELAM-
luciferase reporter, which can be activated by LPS-inducedNFB trans-
location, was co-transfected togetherwith varying amounts of theMon-
arch-1 expression vector. Cells were treated with LPS, and ELAM-
luciferase reporter activity was measured. Transfection of increasing
amounts ofMonarch-1 reduced LPS-stimulated ELAM reporter activa-
tion in a dose-dependent manner (Fig. 2A). The inhibitory effect of
Monarch-1 was observed at both low and high concentrations of LPS
but may be suboptimal because of the strong signal provided by over-
expression of exogenous TLR4, MD-2, and CD14. To bypass the
requirement for overexpression of all three components to reconstitute
an LPS-responsive receptor complex, we examined the effect of Mon-
arch-1 on the ability of the TLR signaling proteinsMyD88, IRAK-1, and
TRAF6 as well as the NFB subunit p65 to transactivate the NFB
luciferase reporter. This reporter consists of three copies of the NFB
binding site linked to a luciferase gene. MyD88, IRAK-1, TRAF6, and
p65 overexpression caused a dramatic induction of NFB activation
(Fig. 2B). Co-transfection of a Monarch-1 expression plasmid resulted
in decreasedNFB activity induced byMyD88, IRAK-1, andTRAF6 but
not by p65. This indicatesMonarch-1 functions upstream of p65. In the
experiments below we show that Monarch-1 interferes with IRAK-1
function. Another report3 shows that Monarch-1 also interferes with
the downstream NFB-inducing kinase, which explains the inhibition
of TRAF6-activated NFB by Monarch-1. This is consistent with the
data in Fig. 2A, which measured the affect on an LPS-responsive recep-
tor complex. These data indicate that the observed capacity of Mon-
arch-1 to diminish TLR signaling is mediated through its effect on
MyD88 and/or IRAK-1 and TRAF6 but not at the level of p65, resulting
in reduced NFB activity.
3 J. Lich, submitted for publication.
FIGURE 1. TLR activation reduces Monarch-1
expression. A, Monarch-1 expression in human
adherent peripheral blood cells stimulated for 1 h
with commercial LPS (TLR4 agonist) or commercial
peptidoglycan (PGN) (TLR2 agonist). Seven sepa-
rate cell preparations were used. B, Monarch-1
expression in human peripheral blood granulo-
cytes stimulated with commercial LPS (TLR4 ago-
nist) or commercial peptidoglycan (TLR2 agonist).
Three separate cell preparations were used. C,
Monarch-1 expression in human peripheral blood
granulocytes stimulated with purified phenol LPS
(TLR4 agonist) or synthetic Pam3Cys (TLR2 ago-
nist). Two separate cell preparations were used.D,
Monarch-1 expression in human adherent periph-
eral blood cells stimulated with purified phenol
LPS (TLR4 agonist) or TNF for 1 h (black bars) and
6h (whitebars). Dataare representativeof twosep-
arate experiments. E,Monarch-1 expression in the
human THP-1 monocyte cell line stimulated with
phenol-purified LPS for the indicated time points.
Data are the average of three separate experi-
ments. Monarch-1 expression was normalized to
the expressionof 18 S rRNAandare represented as
-fold difference compared with control. Error bars
represent the S.E. of separate experiments. F, Mon-
arch-1 protein expression in the human THP-1
monocyte cell line stimulated with Pam3Cys for
the indicated time points. Lysates were immuno-
precipitated (IP) with rabbit anti-Monarch-1 and
rat anti-actin followed by immunoblotting (IB)
with eithermouse anti-Monarch-1 or goat anti-ac-
tin-HRP antibodies. Data are representative of two
separate experiments.
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To determine whether the negative regulatory effect of Monarch-1 is
restricted to the TLR pathway, we next sought to investigate if Mon-
arch-1 could regulate the TNFR pathway. HEK293T cells were trans-
fected with different amounts of Monarch-1 expression vector and
either stimulated with TNF or co-transfected with expression vectors
for TNFR signaling molecules, TRAF2 or RIP1 (Fig. 2C). Overexpres-
sion of Monarch-1 resulted in decreased NFB activity induced by
TNF, TRAF2, or RIP1. Monarch-1 did not suppress the activation of
an HLA-DR luciferase reporter, suggesting that the effects are specific.
These data suggest that Monarch-1 down-regulates both TLR and
TNFR pathways.
Monarch-1 Associates with IRAK-1 and Down-regulates IRAK-1
Activation—One mechanism by which Monarch-1 could reduce TLR
signaling protein-induced NFB activity may be through its association
with the signaling complex. It is currently believed that once MyD88 is
recruited to the TLR4 complex, and it in turn recruits IRAK-4 to a
region between the MyD88 TIR and death domain and IRAK-1 to its
death domain (40). IRAK-4 is believed to phosphorylate IRAK-1, lead-
ing to autophosphorylation and hyperphosphorylation of IRAK-1 (41).
To investigate the mechanism of reduced TLR signaling byMonarch-1,
HEK293T cells were co-transfected with expression vectors for Mon-
arch-1 and the TLR signaling proteins MyD88 or IRAK-1 followed by
immunoprecipitation. Immunoprecipitation of FLAG-tagged IRAK-1
was performed by using anti-FLAG antibody followed by immunoblot-
ting for HA-tagged Monarch-1 using an anti-HA antibody. Monarch-1
was found to co-precipitate with IRAK-1, indicating that these proteins
interact in situ (Fig. 3A). In contrast, no association was detected
between Monarch-1 and MyD88 in experiments in which HA-tagged
MyD88 was immunoprecipitated using anti-HA antibody, and immu-
noblots were probed with anti-FLAG antibody to detect FLAG-tagged
Monarch-1 (Fig. 3B). Upon IRAK-1 overexpression, both native and
phosphorylated forms of IRAK-1 could be visualized by Western anal-
ysis, providing a convenient surrogate for IRAK-1 activation in the
absence of extracellular stimuli (Fig. 3C, lane 3) (28). Because IRAK-1
activation is regulated by sequential phosphorylation events (28), it is
possible to distinguish between the species that is first phosphorylated
by IRAK4 (resulting in the appearance of a single band that migrates
more slowly than native IRAK-1 during SDS-PAGE) (40, 41) and the
hyperphosphorylated species that is the consequence of autophospho-
rylation (28). The appearance of hyperphosphorylated IRAK-1 was
nearly eliminated by the presence of Monarch-1, suggesting inhibition
of IRAK-1 autophosphorylation (Fig. 3C, lane 2, band III). In contrast,
the faster migrating protein bands (Fig. 3C, bands I and II, respectively)
corresponding to both native and IRAK4-phosphorylated IRAK-1 were
not affected, demonstrating specificity for the inhibition of
hyperphosphorylation.
Presence of the NBD Domain Is Associated with Reduced IRAK-1
Activation—Common to all CLR proteins, Monarch-1 consists of three
distinct domains. To determine the domain(s) responsible for IRAK-1
association, truncation mutants were constructed that consisted of the
N-terminal pyrin domain and the C-terminal LRR domain alone or in
combination with theNBD. The analysis of NBD alone was not possible
because this domain appeared to be very unstable in the absence of
either PyD or LRR (not shown). These truncation mutants (shown in
Fig. 4A) were transfected along with recombinant IRAK-1 into
HEK293T cells. Protein complexes were then immunoprecipitatedwith
anti-IRAK-1-specific antibodies. These experiments revealed that
IRAK-1 association is dependent upon the presence of the NBD region
in the presence of either PyD or LRR. Both PyD-NBD and NBD-LRR
interactedwith IRAK-1 (Fig. 4C). Neither the pyrin domain (Fig. 4B) nor
the LRR region (Fig. 4C) alone formed molecular complexes with over-
expressed IRAK-1. Incongruent with this, the analysis of IRAK-1 in
cellular lysate demonstrated that the reduction of IRAK-1 hyperphos-
phorylation (Form III) was most dramatic in the presence of the NBD-
LRR mutant followed by the PyD-NBD mutants (Fig. 4D).
Monarch-1 Associates with IRAK-1 and Prevents Its Activation in
THP-1 Cells—The previous experiment utilized HEK293T cells. To
determine whether Monarch-1 negatively regulates IRAK-1 activation
in a more physiologically relevant system, human monocytic THP-1
FIGURE 2. Monarch-1 blocks signaling mole-
cules in theTLRandTNFRpathways.A, HEK293T
cells were co-transected with TLR4, CD14, MD-2,
different amounts of Monarch-1, and an ELAM-lu-
ciferase reporter construct. After 24 h cells were
stimulated with the indicated concentration of
purified E. coli K235 LPS for 5 h. Results represent
the mean S.E. of three separate experiments. B,
HEK293T cellswere co-transfectedwith either vec-
tor alone or expression plasmids for MyD88,
IRAK-1, TRAF6, or P65 with/without three concen-
trations of Monarch-1, and an NFB luciferase
reporter construct. The results represent the
mean  S.E. of three separate experiments. C,
HEK293T cellswere co-transfectedwith either vec-
tor alone or expression plasmids for TRAF2 or RIP1
or stimulated for 8 hwith TNFwith/without three
concentrations of Monarch-1 and an NFB lucifer-
ase reporter construct. As a control, cells were co-
transfected with an expression plasmid for class II
transactivator (CIITA) and an HLA-DR luciferase
reporter construct plus either vector alone or the
highest concentration of Monarch-1 plasmid. The
results are representative of four separate
experiments.
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cells that stably expressed HA-tagged Monarch-1 (THP-Mon) were
produced (Fig. 5). Endogenous IRAK-1 containing protein complexes
were immunoprecipitatedwith an IRAK-1-specific antibody, andWest-
ern blots were probed with anti-HA to detect co-precipitating Mon-
arch-1. Complex formation between IRAK-1 and Monarch-1 was
induced after Pam3Cys treatment (Fig. 5B, top panel, lanes 2–4). In
contrast, no Monarch-1 was detected in IRAK-1 immunoprecipitates
derived from resting cells, indicating a dependence upon TLR signaling
(Fig. 5B, top panel, lane 1). Notably, when these Western blots were
re-probed to detect immunoprecipitated IRAK-1, sharply reduced lev-
els of hyperphosphorylated IRAK-1 were detected in THP-Mon cells as
compared with their empty vector controls (compare the second panel,
Fig. 5, A and B). This supports the data derived from transient transfec-
tion experiments in HEK293T cells and confirms a role for Monarch-1
in reducing the accumulation of hyperphosphorylated IRAK-1 in
monocytes. These results demonstrate that Monarch-1 associates with
IRAK-1 upon TLR stimulation and inhibits the accumulation of hyper-
phosphorylated IRAK-1. Together these data provide a mechanism by
which Monarch-1 inhibits TLR induced NFB activation.
EndogenousMonarch-1 Functions as aNegative Regulator inMyeloid
Cells—The observation thatMonarch-1 expression is rapidly decreased
after TLR stimulation and that Monarch-1 is a negative regulator of
inflammatory gene activity suggest thatMonarch-1may be involved in
reducing the inflammatory response to pathogens. Specifically, it may
be necessary for innate immune cells to reduce Monarch-1 expression
in response to pathogens to allow for an increase in inflammatory gene
induction. If this hypothesis were correct, the ablation of Monarch-1
expression in myeloid cells would be predicted to result in increased
TLR-induced activation signals. To investigate this,Monarch-1-specific
siRNAswere generated to reduce endogenousMonarch-1 expression in
the THP-1 myeloid cell line. Because of the difficulty in transfecting
human myeloid/monocytic cell lines in general and THP-1 cells specif-
ically, a retroviral based vector was used to express Monarch-1-specific
siRNAs (Fig. 6A). Two sets of siRNAs specific for distinct regions of the
Monarch-1 transcript (designated as siRNA#1 and siRNA#2) were uti-
lized to control for potential nonspecific affects of siRNA. As further
controls, corresponding mutant siRNA with two mutated nucleotides
(designated as mutMon#1 and mutMon#2) were generated to ensure
that the observed effects of siRNA are specific.Monarch-1 short hairpin
RNAs were inserted into the pHSPG retroviral vector. Transcription of
siRNAs were driven by the H1 RNA gene promoter situated immedi-
ately upstream of the insertion site in the 3 LTR. A phosphoglycerate
kinase promoter that drives transcription of the enhanced green fluo-
rescent protein permitted transduced cells to be separated by fluores-
FIGURE 3.Monarch-1 associates with IRAK-1 and limits the accumulation of hyper-
phosphorylated forms of the kinase. A, HEK293T cells were transfected with the indi-
cated plasmidDNA. Twenty-four hours laterwhole cell lysates (WCL) were prepared, and
FLAG-IRAK-1-containing protein complexes were immunoprecipitated (IP) with anti-
FLAG (Fg) M2-agarose beads and separated by SDS-PAGE. Western blots (IB) were
probed with anti-HA (Ha) antibody to detect co-precipitating HA-Monarch-1. p-, phos-
phorylated. B, cells were transfected with empty vector or expression vectors for FLAG-
tagged Monarch-1 and HA-MyD88. MyD88-containing protein complexes were immu-
noprecipitated with an anti-HA antibody and separated by SDS-PAGE. Western blots
were probed with anti-FLAG to detect co-precipitating FLAG-Monarch-1. C, cells were
transfected with the indicated plasmid DNA, and 24 h later whole cell lysates were pre-
pared and separated by SDS-PAGE. Western blots were probed with the indicated anti-
bodies. The hyperphosphorylated form of IRAK-1 (marked as III) was greatly reduced by
the presence of Monarch-1.
FIGURE 4. The Monarch-1 NBD is required for the association and regulation of
IRAK-1 hyperphosphorylation.A, diagramdepicting V5-taggedMonarch-1 truncation
mutants. B, cells were transfected with expression vectors encoding the V5-tagged PyD
of Monarch-1 and HA-IRAK-1. IRAK-1-containing protein complexes were immunopre-
cipitated (IP) with an anti-IRAK-1 antibody and separated by SDS-PAGE. Western blots
(IB) were probedwith anti-V5 to detect co-precipitatingV5-PyD.C, cellswere transfected
with expression vectors encoding the indicated V5-tagged truncation mutant of Mon-
arch-1 in addition to HA-IRAK-1. IRAK-1-containing protein complexes were immuno-
precipitated with an anti-IRAK-1 antibody and separated by SDS-PAGE. Western blots
were probed with anti-V5 to detect co-precipitating V5-tagged Monarch-1 truncation
mutants. D, whole cell lysates derived from experiments described in A and B were
separated by SDS-PAGE and probed with an anti-IRAK-1 antibody. The hyperphospho-
rylated form of IRAK-1 (marked as III) was greatly reduced in the presence of the NBD-
LRR-containing truncation mutant of Monarch-1.
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cence-activated cell sorting. Therefore, the THP-1 monocytic cell line
was transduced with the siRNA-containing constructs and their corre-
sponding controls. Sorted enhanced green fluorescent protein-positive
cells were maintained in bulk culture and used to investigate endoge-
nous Monarch-1 function. Expression of Monarch-1 in the four cell
samples were assessed by real-time PCR (Fig. 6B). Compared with their
controls, both siRNA#1 and siRNA#2 achieved greater than 70% reduc-
tion in endogenous Monarch-1 expression. To assess the level of NFB
activity in theMonarch-1 siRNA cells, the siRNA cells and their mutant
controls were transduced with a retrovirus that contained the luciferase
reporter driven by the NFB-responsive promoter element 5 NFB
response element and TATA box from pNFBluc (Stratagene). Cells
were stimulated with phenol-purified LPS derived from E. coli K235 for
6 h followed by analysis of NFB luciferase activity. If Monarch-1 were
a negative regulator of pro-inflammatory signaling, ablation of the neg-
ative regulatory activity of Monarch-1 would result in an increase in
NFB activity. Indeed, reducedMonarch-1 expression achieved by the
siRNA resulted in a 1000-fold increase in NFB luciferase reporter
FIGURE 5.Monarch-1 associates with endogenous IRAK-1 in THP-1 monocytic cells
upon TLR stimulation and limits the accumulation of hyperphosphorylated,
endogenous IRAK-1. THP-1 cells stably expressing (A) empty vector (THP-HA-EV) or (B)
HA-taggedMonarch-1 (THP-HA-Mon) were stimulated with the TLR2 agonist Pam3Cys4
for the indicated times. Endogenous IRAK-1-containing protein complexes were immu-
noprecipitated (IP) with an anti-IRAK-1 antibody and then fractionated by SDS-PAGE.
Western blots were probed with anti-HA to detect co-precipitating HA-Monarch-1 (top
panels). These immunoblots (IB) were then stripped and probed with anti-IRAK-1 anti-
bodies (second panels). The hyperphosphorylated formof IRAK-1was greatly reducedby
the presence of Monarch-1. Interestingly, analysis of cellular lysates indicated that the
disappearance of the 80-kDa nonphosphorylated form of IRAK-1 occurs more slowly in
the presence of Monarch-1. Actin immunoblots were performed to ensure equivalent
levels of protein were used among the samples. p-, phosphorylated.
FIGURE 6. Monarch-1 is a negative regulator of NFB activity in the THP-1 mono-
cytic cell line.A, plasmidmapofMonarch-1 siRNA in thepHSPG retroviral vector. SiRNAs
specific forMonarch-1were developed to blockMonarch-1 expression followed by anal-
ysis of gene activity. Monarch-1 siRNAs, driven by the H1 RNA promoter, were inserted
into the pHSPG retroviral vector within the 3 LTR. The presence of a phosphoglycerate
kinase (PGK) promoter driving enhanced green fluorescent protein (eGFP) allows for
selection of transduced cells by fluorescence-activated cell sorting. Two separateMon-
arch-1 siRNAs and their correspondingmutant, controlswereplaced inpHSPGvectors.B,
analysis ofMonarch-1 expression inMonarch-1 (Mon-1) and control mutant (mutMon-1)
siRNA bulk monocyte THP-1 cultures as determined by real-time PCR. THP-1 cells were
infected with two different Monarch-1-specific siRNAs, siRNA#1 and siRNA#2, respec-
tively. Expressionwasnormalized to the expressionof 18 SmRNAandare represented as
-fold over mutant control. The results represent the mean S.E. of five separate exper-
iments. C, analysis of NFB activity in Monarch-1-specific siRNA cultures. Monarch-1
(Mon-1) and control mutant (mutMon-1) siRNA cultures were infected with a retroviral
based NFB luciferase reporter. Cultures were then stimulated with E. coli K235 LPS fol-
lowed by analysis of NFB luciferase activity. Expression is represented as -fold over
mutant control. Results represent the mean S.E. of three separate experiments.
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activity compared with the control mutant siRNA (Fig. 6C). Basal levels
of NFB reporter activity were higher in the Monarch-1 siRNA cells
than in their mutant control cells, suggesting that endogenous Mon-
arch-1 functions to suppress NFB activity in the absence of stimula-
tion. Monarch-1 siRNA#2 cells stimulated with LPS had increased
NFB activity, although the levels were less dramatic (data not shown).
These data suggest that endogenous Monarch-1 functions to dampen
NFB activation.
Monarch-1 Is a Negative Regulator of IL-6 Cytokine Expression in
Response to TLR Agonists—The experiment shown above supports the
previous hypothesis thatMonarch-1 functions as a negative regulator of
TLR4-induced NFB activity as assessed by an NFB reporter assay. To
further investigate the function ofMonarch-1 in mediating the inflam-
matory response to pathogens, we tested whether endogenous Mon-
arch-1 could regulate the IL-6 gene induced by TLR activation. Both
siRNA#1 and siRNA#2 THP-1 cells were stimulated with E. coli K235
LPS for 6 h followed by analysis of IL-6 mRNA expression by real-time
PCR. Stimulation of both siRNA#1 and siRNA#2 (Mon-1) THP-1 cells
resulted in a 4-fold increase in IL-6 mRNA expression compared with
mutant controls (mutMon-1) (Fig. 7A). To investigate if the increased
IL-6 expression were also observed at the protein level, supernatants
from LPS-stimulated Monarch-1 siRNA#1 and siRNA#2 THP-1 cells
were analyzed for IL-6 cytokine expression by ELISA. Consistent with
the mRNA data, both Monarch-1 siRNA-containing lines exhibited
increased IL-6 protein expression compared with their mutant controls
(Fig. 7B). These data suggest that endogenousMonarch-1 functions as a
negative regulator of IL-6 cytokine expression in response to TLR
stimulation.
Monarch-1 Is a Negative Regulator of IL-6 Cytokine Expression in
Response to M. tuberculosis Infection—The above observation was
obtained with a pure TLR agonist. To assess if this observation could be
extended to a clinically relevant live human pathogen, cells were
infected with M. tuberculosis. M. tuberculosis, the causative agent of
human tuberculosis, is the most prevalent and deadly bacterial infec-
tious disease worldwide and affects one-third of the world population
(42). Incomplete understanding of the molecular nature of protective
immune responses has hampered the development of more effective
vaccines and therapies.M. tuberculosis leads to the induction of inflam-
matory cytokines through the activation of TLRs (43). To determine
whether exposure of cells toM. tuberculosis could regulateMonarch-1
expression, THP-1 cells were infected with the virulent H37Rv strain of
M. tuberculosis for the indicated time points (Fig. 8A). Monarch-1
expression was reduced after exposure of cells to liveM. tuberculosis for
2 h, and the expression was nearly abolished after 4 h of exposure. This
further suggests that down-regulation of Monarch-1 may be required
for the normal defensive response to microorganisms. Because IL-6 is
an important response of the innate immune cells to infection by M.
tuberculosis (43), we determined if exposure ofMonarch-1 siRNA cells
to live bacilli would also result in increased IL-6 cytokine expression.
Monarch-1 siRNATHP-1 cells were infectedwith the virulentM. tuber-
culosis followed by analysis of IL-6 cytokine expression by real-time
PCR (Fig. 8B). The bacilli caused a dramatic enhancement of IL-6 pro-
duction, but cells containing siRNA#1 or siRNA#2 had much higher
expression of IL-6 cytokine compared with both wild-type THP-1 cells
and the mutant control siRNA.
Monarch-1 Is a Negative Regulator of TLR2-, TLR4- and TNFR-me-
diated Cytokine Secretion—To investigate more broadly the function of
Monarch-1 in mediating the inflammatory response to TLR agonists as
well as TNF, we investigated whether endogenous Monarch-1 could
regulate pro-inflammatory genes in addition to IL-6. We also investi-
gated if Monarch-1 could mediate inflammatory responses by other
TLR agonists. Taking into consideration that Monarch-1 inhibits
FIGURE 7.Monarch-1 is a negative regulator of
IL-6 in monocytic THP-1 cells induced by LPS.
Analysis of IL-6 mRNA and protein expression in
Monarch-1-specific siRNA cultures.A, twodifferent
Monarch-1 (Mon-1) and control mutant (mut-
Mon-1) siRNA cultures, siRNA#1 and siRNA#2,were
stimulated with E. coli K235 LPS followed by anal-
ysis of IL-6 transcript expression by real-time PCR.
IL-6 expression was normalized to 18 S RNA and
are represented as exponential numbers. Data are
a representative of five separate experiments. B,
two different Monarch-1 (Mon-1) and control
mutant (mutMon-1) siRNA cultures, siRNA#1 and
siRNA#2, were stimulated with E. coli K235 LPS fol-
lowed by analysis of IL-6 cytokine expression by
ELISA. Data are representative of three separate
experiments. ND, not determined.
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IRAK-1 function, a downstream signaling protein common to both the
TLR2 andTLR4 pathway, we stimulated THP-1Monarch-1 siRNA cells
with E. coli K235 LPS (TLR4) and with the synthetic TLR2 agonist,
Pam3Cys, in three separate experiments. To investigate the role of
endogenousMonarch-1 in regulating the TNFR pathway, we also stim-
ulated these cells with TNF. Stimulation by Pam3Cys in general
resulted in higher cytokine levels than that observed after LPS stimula-
tion. Supernatant from stimulated cells was analyzed using the Human
Inflammation Cytokine Bead Array (Bio-Rad). In Monarch-1 siRNA
cells we observed increased levels of IL-6, IL-1, TNF and a slight
increase in IL-8 when compared with mutMon-1 control cells (Fig. 9A)
upon stimulation with Pam3Cys. Among LPS-treated Monarch-1
siRNA containing cells, an increase in IL-6 and IL-1 was observed.
TNF and IL-8 were expressed at similar levels in Monarch-1 siRNA
cells compared with the mutant control (Fig. 9B). However, TNF pro-
duction in LPS-treated THP-1 cells was low, and the data should not be
over-interpreted. Finally, in response to TNF,Monarch-1 siRNA cells
produced higher levels of IL-1 with a modest increase in IL-8 com-
pared with control cells (Fig. 9C). These data support the observation
that Monarch-1 broadly down-regulates TLR signaling by a TLR2 ago-
nist. It also caused amore specific down-regulation of IL-6 and IL-1 by
a TLR4 agonist. These findings also support the observation that Mon-
arch-1 is a negative regulator of the TNFR receptor pathway. In a sep-
arate set of experiments using microarray analysis we determined that
other genes were not affected by Monarch-1 including lymphotoxin ,
lymphotoxin , TGF1, CCL1 (data not shown). Taken together, these
date imply that Monarch-1 is a broad inhibitor of both TLR and TNFR
signal transduction pathways
DISCUSSION
The inflammatory response to infection represents a two-edged
sword, whereas a proper pro-inflammatory response is necessary to
contain infectiousmicroorganisms and foreign antigens, an overzealous
response is detrimental to the host (44). The impact of the latter is
clearly demonstrated by the 660,000 cases of sepsis per year with a 20%
mortality rate (45). Although an array of positive regulators of inflam-
mation has been discovered, relatively few negative feedback modula-
tors have been identified. The SOCS (suppressor of cytokine signaling)
molecules represent a major class of negative regulators that are gener-
ally induced by stimulants, including TLR agonists (44). Like SOCS,
IRAK-M is also induced by TLR agonists. Studies using the inactive
kinase IRAK-M-deficient mice reveal that IRAK-M is a negative regu-
lator of TLR signaling and acts by inhibiting the dissociation of IRAK-
1/IRAK-4 from the TLR4/MyD88 complex, resulting in blocking of
downstream NFB activation (46). An alternatively spliced form of
MyD88, called MyD88s, binds to TLRs but cannot interact with
IRAK-4. As a result, phosphorylation of IRAK-1 does not occur, and
NFB activation is abrogated (40, 47). The cytokine-inducible zinc fin-
ger protein called A20 and A20-like proteins including ZNF216 and the
zinc finger protein TIZ have been found to inhibit IL-1/TLR4-mediated
activation of NFB (48). Recently, several CLR proteins are shown to
negatively affect cell activation pathways (49–51). In this report we
show that Monarch-1 is also a negative regulator of pro-inflammatory
responses. However, it is the first to exhibit an inhibitory effect on the
TLR signaling pathway induced byMyD88/IRAK-1/TRAF6 and specif-
ically on IRAK-1 activation.
The conclusion thatMonarch-1 is a CLR proteinwith an anti-inflam-
matory function ismost convincingly demonstrated by the use of siRNA
in myeloid/monocytic cells. Monarch-1 is a negative regulator of both
the TLR and TNFR pathways. Because Monarch-1 is the first CLR pro-
tein that interferes with both TLR2 and TLR4 activation, we explored
themolecularmechanismbywhichMonarch-1 interfereswith this acti-
vation. We show that Monarch-1 blocks TLR signaling by association
with IRAK-1 and inhibition of IRAK-1 hyperphosphorylation. IRAK-1
activation is regulated by sequential phosphorylation events involving
the initial phosphorylation by IRAK4 and subsequent hyperphosphory-
lation by IRAK-1 itself. The hyperphosphorylation of IRAK-1 is impor-
tant for TLR signal transduction because it serves to decrease affinity for
the TLR receptor complex, which is required for TRAF6 binding and
subsequent downstream signal transduction (28). Our results show that
Monarch-1 clearly interferes with the hyperphosphorylation of IRAK-1.
Consistent with these findings, mitigated IRAK-1 hyperphosphoryla-
tion has been observed in endotoxin-tolerant cells, where LPS exposure
no longer stimulates NFB activation (52, 53). This is thought to be
secondary to a failure to recruit MyD88 to the TLR4 receptor complex
(53) and the subsequent failure to recruit IRAK-1 appropriately to
MyD88 (52). In addition, an inhibitory splice variant ofMyD88 has been
shown to block phosphorylation of IRAK-1, leading to the inhibition of
LPS-induced NFB activation (40). Thus, phosphorylation of IRAK-1 is
emerging as a critical regulatory step in the control of TLR signaling and
Monarch-1 is an inhibitor of this important pathway.
An emerging theme among a subgroup of CLRs is that they exhibit
negative regulatory function. Among these, CLR16.2 is unique in its
down-regulation of T cell receptor-mediated cellular activation of
NFB, AP-1, and NFAT (49). PAN1 down-regulates NFB and the
expression of NFB regulated genes in a monocytic cell line (50).
PYPAF3 down-regulates LPS-stimulated IL-1 production (51). Both
the PAN1 study and the present work relied on the reduction of endog-
enous CLR by siRNA. Thus, these two reports provide powerful evi-
FIGURE 8.Monarch-1 is a negative regulator of IL-6 in the THP-1monocytic cell line
infected with virulent M. tuberculosis. A, Monarch-1 transcript expression in the
human THP-1 monocytic cell line infected with virulent M. tuberculosis (Mtb) for the
indicated time points. Data represent the average of three separate experiments meas-
ured by real-time PCR. B, analysis of IL-6 mRNA expression in Monarch-1-specific siRNA
cultures. THP-1 cells were compared withMonarch-1 (Mon-1) and control mutant (mut-
Mon-1) siRNA cultures after infection with M. tuberculosis followed by analysis of IL-6
expressionby real-timePCR. Expressionwasnormalized to 18 SRNA, anddata are shown
as -fold over unstimulated control. Data are representative of three separate
experiments.
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dence that a subgroup of CLRs represents negative regulators of
immune and inflammatory activation.
In conclusion, this work supports the hypothesis that Monarch-1
normally functions as a negative regulator of inflammatory activity in
resting monocytic/myeloid cells, but its expression is down-regulated
by TLR agonists, TNF, or whole pathogens. This down-regulation is
necessary for proper inflammatory and anti-microbial responses to pro-
ceed. The down-regulation of Monarch-1 expression is not specific to
M. tuberculosis as we have also observed a decrease of Monarch-1
expression in cells infected with other pathogens (data not shown).
Monarch-1 down-regulates LPS-inducedNFB reporter activity in cells
co-transfected with TLR4 and in cells co-transfected with the TLR/IL-1
receptor signaling mediatorsMyD88, IRAK-1, and TRAF6. This inhibi-
tion is not specific to theTLRpathway asMonarch-1 also inhibits TNFR
signaling mediators such as TRAF2 and RIP1. Monarch-1 is likely to
inhibit multiple pathways, although a focus on the TLR pathway in this
report shows that it interfereswith IRAK-1 hyperphosphorylation. Inhi-
bition of Monarch-1 by siRNA in cell types that naturally express it
significantly altered NFB activation and proinflammatory cytokine
synthesis in response to TLR agonists, TNF, and virulentM. tubercu-
losis. A greater understanding of the ability of Monarch-1 to modulate
the immune response to pathogens including M. tuberculosis will
enhance the development of more effective vaccines and therapies.
Taken together these data provide compelling evidence thatMonarch-1
is a novel negative regulator of TLR- and pathogen-mediated pro-in-
flammatory gene induction through its interaction with IRAK-1 and its
inhibition of IRAK-1 hyperphosphorylation
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